SPI112 is a selective inhibitor of the SHP2 phosphatase, an enzyme involved in the RAS/MAPK signaling pathway, which plays a key role in cell growth and differentiation. Due to its ability to modulate this pathway, SPI112 has shown potential in the treatment of cancers driven by mutations in this signaling cascade, particularly those involving RTK, KRAS, or NF1. It is being investigated for use in tumors that are resistant to other targeted therapies, including certain types of lung, breast, and pancreatic cancers. SPI112 demonstrates activity both as a single agent and in combination with other inhibitors such as MEK or EGFR inhibitors, enhancing anti-tumor effects in preclinical models. Its development supports ongoing efforts to target oncogenic signaling pathways with greater precision and overcome therapeutic resistance.